ASP 3026

Product Description

ASP 3026 is a potent anaplastic lymphoma kinase (ALK) inhibitor (IC₅₀ = 3.5 nM). Also inhibits Ack and ROS1 activity (IC₅₀ values are 5.8 and 8.9 nM respectively). Attenuates proliferation, and induces apoptosis of NPM-ALK⁺ T cell anaplastic large-cell lymphoma (ALCL) cells in vitro. Suppresses tumor growth of NPM-ALK⁺ ALCL cell xenografts in mice. Causes tumor shrinkage in hEML4-ALK transgenic mice. Orally available.

Solubility

Preparing Stock Solutions for ASP 3026

The following data is based on the product molecular weight 580.74

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	8.61 mL	43.05 mL	86.10 mL
1 mM	1.72 mL	8.61 mL	17.22 mL
2 mM	0.86 mL	4.30 mL	8.61 mL
10 mM	0.17 mL	0.86 mL	1.72 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Awad and Shaw ALK Inhibitors in Non-Small Cell Lung Cancer: Crizotinib and Beyond. Clin.Adv.Hematol.Oncol. 2014 PMID: 25322323
• Mori The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Mol.Cancer Ther. 2014 PMID: 24419060
• George The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget 2014 PMID: 25026277